摘要
背景/目的:Prothymosin Alpha:(proTα)是1984年Haritos首先分离出的普遍存在的多肽,其作用仍然部分难以捉摸。我们知道proTα在细胞内作为一种抗凋亡和增殖介质和细胞外作为一种生物反应调节剂,类似于称为“报警器”的分子介导免疫反应。我们的研究团队率先阐明了proTα观察到的活性的机制。 结果:我们首次证明proTα水平在正常和异常细胞增殖期间增加。我们显示proTα多效作用,诱导对免疫细胞群的免疫调节作用。我们发现proTα的免疫反应区是羧基末端十肽proTα(100-109),两个分子都刺激先天免疫应答,通过Toll样受体(TLR),特别是TLR-4信号传导。我们报道proTα和proTα(100-109)在涉及TLR-4的位点上结合人嗜中性粒细胞的表面,细胞活化被细胞质钙离子流入补充。此外,我们显示proTα和proTα(100-109)作为淋巴细胞刺激上游的佐剂,并且在抗原存在下促进抗原反应性效应物的扩增。最近,我们报道proTα(100-109)可能在实验发炎部位积累,可以作为严重细菌感染的替代生物标志物,提出proTα或proTα(100-109)的细胞外释放在免疫系统的条件 危险。 结论:因此,我们建议proTα和可能的proTα(100-109)作为报警器,作为重要的免疫介质和生物标志物,并且最终可能成为免疫相关疾病如癌症,炎症中的新的治疗/诊断方法的靶标 和败血症。
关键词: Prothymosin alpha,proTα(100-109),惊厥症,癌症,炎症,败血症。
Current Medicinal Chemistry
Title:Prothymosin Alpha: An Alarmin and More...
Volume: 24 Issue: 17
关键词: Prothymosin alpha,proTα(100-109),惊厥症,癌症,炎症,败血症。
摘要: Background/Objective: Prothymosin alpha (proTα) is a ubiquitous polypeptide first isolated by Haritos in 1984, whose role still remains partly elusive. We know that proTα acts both, intracellularly, as an anti-apoptotic and proliferation mediator, and extracellularly, as a biologic response modifier mediating immune responses similarly to molecules termed as “alarmins”. Our research team pioneered the elucidation of the mechanisms underlying the observed activities of proTα.
Results: We were the first to demonstrate that proTα levels increase during normal and abnormal cell proliferation. We showed that proTα acts pleiotropically, inducing immunomodulatory effects on immune cell populations. We revealed that the immunoreactive region of proTα is the carboxyterminal decapeptide proTα(100-109) and both molecules stimulate innate immune responses, signaling through Toll-like receptors (TLRs), specifically TLR-4. We reported that proTα and proTα(100-109) bind on the surface of human neutrophils on sites involving TLR-4, and cell activation is complemented by cytoplasmic calcium ion influx. Further, we showed that proTα and proTα(100-109) act as adjuvants upstream of lymphocyte stimulation and, in the presence of antigen, promote the expansion of antigen-reactive effectors. Most recently, we reported that proTα(100-109) may accumulate in experimentally inflamed sites and can serve as a surrogate biomarker in severe bacterial infections, proposing that extracellular release of proTα or proTα(100- 109) alerts the immune system during conditions of danger. Conclusion: We, therefore, suggest that proTα, and likely proTα(100-109), act as alarmins, being important immune mediators as well as biomarkers, and could eventually become targets for new therapeutic/diagnostic approaches in immune-related diseases like cancer, inflammation, and sepsis.Export Options
About this article
Cite this article as:
Prothymosin Alpha: An Alarmin and More..., Current Medicinal Chemistry 2017; 24 (17) . https://dx.doi.org/10.2174/0929867324666170518110033
DOI https://dx.doi.org/10.2174/0929867324666170518110033 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Transcriptome in Blood: Challenges and Solutions for Robust Expression Profiling
Current Molecular Medicine Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Anti-Cancer Agents in Medicinal Chemistry The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Current Clinical Pharmacology Immunomodulatory and Anti-inflammatory Properties of Artesunate in Experimental Colitis
Current Medicinal Chemistry Magnetic Iron Oxide Nanoparticles for Tumor-Targeted Therapy
Current Cancer Drug Targets Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Improved Drug Delivery System for Cancer Treatment by D-Glucose Conjugation with Eugenol From Natural Product
Current Drug Delivery The Pathogenic Role of Intestinal Flora in IBD and Colon Cancer
Current Drug Targets Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design The Polyhedric Abl Kinases and their Pharmacologic Inhibitors
Current Enzyme Inhibition Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry Structural Characterization of Alpha-methylacyl-CoA Racemase: Comparative Structural Modeling, Molecular Docking and Dynamic Simulations Studies
Current Cancer Drug Targets Dendrimers: A Class of Polymers in the Nanotechnology for the Delivery of Active Pharmaceuticals
Current Pharmaceutical Design Anti-Infective Effects of Lactobacilli in the Gastrointestinal Tract
Current Medicinal Chemistry - Anti-Infective Agents Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy Interactome Analysis of the Differentially Expressed Proteins in Uterine Leiomyoma
Anti-Cancer Agents in Medicinal Chemistry Synthesis of New Cyclopeptide Analogues of the Miuraenamides
Current Organic Synthesis